GB0721856D0 - Compositions for treating parkinsons disease and other cns disorders - Google Patents

Compositions for treating parkinsons disease and other cns disorders

Info

Publication number
GB0721856D0
GB0721856D0 GBGB0721856.3A GB0721856A GB0721856D0 GB 0721856 D0 GB0721856 D0 GB 0721856D0 GB 0721856 A GB0721856 A GB 0721856A GB 0721856 D0 GB0721856 D0 GB 0721856D0
Authority
GB
United Kingdom
Prior art keywords
compositions
cns disorders
parkinsons disease
treating
treating parkinsons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0721856.3A
Other versions
GB2454480A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectura Group PLC
Original Assignee
Vectura Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectura Group PLC filed Critical Vectura Group PLC
Priority to GB0721856A priority Critical patent/GB2454480A/en
Publication of GB0721856D0 publication Critical patent/GB0721856D0/en
Publication of GB2454480A publication Critical patent/GB2454480A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
GB0721856A 2007-11-07 2007-11-07 Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders Withdrawn GB2454480A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0721856A GB2454480A (en) 2007-11-07 2007-11-07 Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0721856A GB2454480A (en) 2007-11-07 2007-11-07 Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders

Publications (2)

Publication Number Publication Date
GB0721856D0 true GB0721856D0 (en) 2007-12-19
GB2454480A GB2454480A (en) 2009-05-13

Family

ID=38858301

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0721856A Withdrawn GB2454480A (en) 2007-11-07 2007-11-07 Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders

Country Status (1)

Country Link
GB (1) GB2454480A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201503129RA (en) * 2012-10-22 2015-05-28 Civitas Therapeutics Inc Levodopa formulations for rapid relief of parkinson's disease
CA2888979A1 (en) * 2012-10-22 2014-05-01 Civitas Therapeutics, Inc. Reducing inter-patient variability of levodopa plasma concentrations
BR112015010601B1 (en) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOSITION
BR112016024502A8 (en) * 2014-04-21 2021-06-29 Civitas Therapeutics Inc use of a dose of fine particles (pdf) of levodopa in the manufacture of a drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
EP2630954B1 (en) * 2002-03-20 2016-10-05 Civitas Therapeutics, Inc. Pulmonary delivery for levodopa

Also Published As

Publication number Publication date
GB2454480A (en) 2009-05-13

Similar Documents

Publication Publication Date Title
HK1255083A1 (en) Methods and compositions for treating pulmonary hypertension
EP2170309A4 (en) Methods and compositions for treating disorders
ZA201002751B (en) Compositions for treating parkinson's disease
HK1145440A1 (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
IL208981B (en) Combination compositions for treating alzheimer disease and related disorders with zonisamide
ZA200809528B (en) Treatment for depressive disorders
EP2010187A4 (en) Compounds for diseases and disorders
IL190913B (en) Compositions for the treatment sweat related disorders
IL184456A0 (en) Dosage form for treating gastrointestinal disorders
EP2083857A4 (en) Methods for treating mica-related disorders
ZA200807015B (en) Dihydrothienopyrimidine for treating inflammatory disorders
IL209032A0 (en) Compositions and methods for treating digestive disorders
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
GB2466912B (en) Compositions and methods for treating lysosomal disorders
IL191168A0 (en) Compositions and methods for treating cns disorders
ZA200809527B (en) Treatment for depressive disorders
HK1164149A1 (en) Compositions for the treatment of gastro-esofageal reflux disease (gerd) -(gerd)
EP1996218A4 (en) Methods and compositions for the treatment of gastrointestinal disorders
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
EP2331097A4 (en) Methods for treating cns disorders
EP2182943A4 (en) Methods and compositions for treating fibrosis related disorders using il-17 antagonists
EP2120994A4 (en) Methods and compositions for treating hypoglycemic disorders
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
HK1129596A1 (en) Methods and compositions for treating disease
GB0721856D0 (en) Compositions for treating parkinsons disease and other cns disorders

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)